Clinical trial
Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting
NCT01079364 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting
- Lead sponsor
- Sanofi
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- January 31, 2010
- Completion date
- July 31, 2012
- Enrollment
- 52 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.